KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $166.0 million.

  • Ionis Pharmaceuticals' Other Non-Current Assets rose 3795.2% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 3795.2%. This contributed to the annual value of $127.3 million for FY2024, which is 2089.48% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Other Non-Current Assets is $166.0 million, which was up 3795.2% from $132.1 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Other Non-Current Assets ranged from a high of $166.0 million in Q3 2025 and a low of $49.0 million during Q3 2021
  • Its 5-year average for Other Non-Current Assets is $92.0 million, with a median of $86.0 million in 2023.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Other Non-Current Assets surged by 672.26% in 2022, and later surged by 7512.37% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Other Non-Current Assets stood at $70.6 million in 2021, then rose by 6.72% to $75.3 million in 2022, then soared by 39.73% to $105.3 million in 2023, then rose by 20.89% to $127.3 million in 2024, then skyrocketed by 30.41% to $166.0 million in 2025.
  • Its Other Non-Current Assets was $166.0 million in Q3 2025, compared to $132.1 million in Q2 2025 and $131.8 million in Q1 2025.